We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

13 hedge funds and large institutions have $389K invested in Phio Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

8% more funds holding

Funds holding: 12 → 13 (+1)

0.87% more ownership

Funds ownership: 1.44% → 2.31% (+0.87%)

13% less capital invested

Capital invested by funds: $445K → $389K (-$56.6K)

Holders
13
Holders Change
+1
Holders Change %
+8.33%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$180K
2
Citadel Advisors
Citadel Advisors
Florida
+$36.4K
3
VF
Virtu Financial
New York
+$21.7K
4
SM
Sabby Management
Florida
+$19K
5
Cetera Investment Advisers
Cetera Investment Advisers
Illinois
+$7.14K

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$22.8K
2
Citigroup
Citigroup
New York
-$1.38K
3
JP Morgan Chase
JP Morgan Chase
New York
-$6
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$131K +$19K +1,850 +11%
AFM
2
Anson Funds Management
Texas
$120K +$180K +17,492 New
Citadel Advisors
3
Citadel Advisors
Florida
$24.2K +$36.4K +3,538 New
Bank of Montreal
4
Bank of Montreal
Ontario, Canada
$19K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$18.5K – – –
BCM
6
Bridgeway Capital Management
Texas
$17.8K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$16K +$1.54K +150 +7%
VF
8
Virtu Financial
New York
$14K +$21.7K +2,116 New
Cetera Investment Advisers
9
Cetera Investment Advisers
Illinois
$12.9K +$7.14K +695 +59%
Cambridge Investment Research Advisors
10
Cambridge Investment Research Advisors
Iowa
$11K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$4.34K +$4.23K +412 +185%
Morgan Stanley
12
Morgan Stanley
New York
$190 +$144 +14 +100%
Wells Fargo
13
Wells Fargo
California
$14 – – –
BlackRock
14
BlackRock
New York
$1 – – –
Geode Capital Management
15
Geode Capital Management
Massachusetts
– -$22.8K -1,692 Closed
Citigroup
16
Citigroup
New York
– -$1.38K -102 Closed
JP Morgan Chase
17
JP Morgan Chase
New York
– -$6 – –

PHIO Hedge Fund Activity: Q4 2023 in Review

13 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2023, worth a combined $389K — down 13% from $445K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new PHIO positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 0 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $180K. The largest seller was Geode Capital Management, exiting entirely with an estimated $22.8K sold.

  • 13 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2023, up from 12 in Q3 2023.
  • Funds reported $389K of Phio Pharmaceuticals stock for Q4 2023, down 13% quarter-over-quarter.
  • 3 funds opened new Phio Pharmaceuticals positions in Q4 2023 and 2 closed out, a net change of +1 holder.
  • The largest Phio Pharmaceuticals buyer in Q4 2023 was Anson Funds Management, an estimated $180K added.
  • The largest Phio Pharmaceuticals seller in Q4 2023 was Geode Capital Management, an estimated $22.8K sold.

Based on aggregated 13F filings for Q4 2023.